Breakthrough in Fighting Skin and Lung Fibrosis
Researchers at The University of Texas at El Paso (UTEP) have made a major breakthrough in treating skin and lung fibrosis — conditions that cause tissues to thicken and stiffen, often leading to severe organ damage. Led by Dr Md Nurunnabi from UTEP’s School of Pharmacy, the team’s new approach promises better treatments and improved quality of life for sufferers.
What is Fibrosis and Why it Matters
Fibrosis happens when connective tissues in organs become abnormally thick and rigid. This can cripple lung function or narrow blood vessels, boosting blood pressure and causing serious health problems. Dr Nurunnabi became fascinated by fibrosis during his postdoctoral training, especially as the COVID-19 pandemic revealed how lung inflammation and fibrosis contributed to many deaths.
Nanotech Targets Fibrosis at Its Source
Instead of killing off damaging cells, Dr Nurunnabi’s team designed nanoparticles that selectively target the cells responsible for fibrosis and stop them from overproducing collagen — the protein that leads to tissue thickening. This clever “cell rehabilitation” method avoids harming healthy cells and delivers promising results.
Lab and Animal Tests Show Stunning Results
The team ran both in vitro (test tube) and in vivo (mouse) experiments. The nanoparticles successfully interrupted fibrosis without damaging healthy tissue. This game-changing discovery could soon lead to safe and effective treatments for fibrosis-related diseases.
Hope for Millions with Fibrosis
Dr José Rivera, founding dean of UTEP’s School of Pharmacy, hailed the research as crucial in battling devastating fibrosis symptoms. Collaborating with the National Institutes of Health, Baylor College of Medicine, and the National Scleroderma Foundation, UTEP’s team is pushing the boundaries of treatment and raising hopes for longer, healthier lives for patients worldwide.
